Key facts
- This page summarizes Xiangmin Cui's Form 4 filing for ALPINE IMMUNE SCIENCES, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jan 2024, 17:48.
Xiangmin Cui - 18 Jan 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 18 Jan 2024
- Net transaction value
- +$15,729,263
- SEC form
- 4
- Accepted by SEC
- 22 Jan 2024, 17:48:23 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 11 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Xiangmin Cui
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Xiangmin Cui filed Form 4 for ALPINE IMMUNE SCIENCES, INC. on 22 Jan 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: +$15,729,263.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALPN
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $15,729,263
- Shares
- +1,234,636
- Change %
- +23%
- Price
- $12.74
- Shares after
- 6,582,380
- Date
- 18 Jan 2024
- Ownership
- See Footnote
- Footnotes
- F1
ALPN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,735,544
- Date
- 18 Jan 2024
- Ownership
- See Footnote
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALPN
transaction
Derivative
Warrant (right to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -1,234,636
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 18 Jan 2024
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 1,234,636
- Exercise price
- $12.74
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
Footnote F2
These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.